Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence

This project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes.

Subsidie
€ 1.995.582
2024

Projectdetails

Introduction

Tumours evolve, transforming from early-stage curable disease into treatment-refractory, deadly cancer. Therapy resistance is arguably the biggest problem in oncology today, and much of it remains unexplained.

Central Hypothesis

The central hypothesis of this proposal is that a large proportion of unexplained drug resistance is due to heritable epigenetic alterations and non-heritable transcriptional plasticity in cancer cells. I refer to these mechanisms as the dark matter of cancer evolution.

Mechanisms of Resistance

Genetic, epigenetic, and transcriptional adaptation, together with changes in the tumour microenvironment, may happen at the same time in the same tumour. Lack of knowledge of these mechanisms hinders the development of new treatment strategies. Tackling drug resistance requires a unique combination of:

  • Clinical cohorts
  • Experimental models
  • Evolutionary biology
  • Computational methods

Research Focus

I will map and quantify the mechanisms and evolutionary dynamics of genetic and non-genetic drug resistance at an unprecedented scale. I will focus on colorectal cancer, the third most common cancer and second leading cause of cancer-related death worldwide.

Methodology

I will use patient-derived organoid models, matched to clinical cohorts followed longitudinally. I will measure organoid evolution under the pressure of cancer drugs, with and without the tumour microenvironment.

Tracking Evolution

I will track cell lineages with lentiviral barcoding and perform longitudinal single-cell multi-omics, measuring genomes, epigenomes, and transcriptomes of the same cell. I will interpret the results within a unique computational framework that brings together evolutionary theory with machine learning to measure, predict, and control resistance.

Expected Outcomes

This project will identify new mechanisms and dynamics of cancer drug resistance, deliver new predictive models, and find novel collateral drug sensitivities. This will allow designing rational drug combinations and schedules that will prevent or delay resistance, drastically improving patient outcomes.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.995.582
Totale projectbegroting€ 1.995.582

Tijdlijn

Startdatum1-3-2024
Einddatum28-2-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • FONDAZIONE HUMAN TECHNOPOLEpenvoerder

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000

Vergelijkbare projecten uit andere regelingen

ERC STG

Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis

EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.

€ 1.500.000
ERC STG

Understanding and targeting cancer persister cells

This project aims to develop tools for studying cancer persister cells using single-cell lineage tracing to enhance understanding and treatment of therapy-resistant tumors.

€ 1.728.750
ERC STG

Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy

This project aims to develop a single-cell multiomics method to understand epigenetic resistance mechanisms in AML, enhancing treatment strategies against drug resistance.

€ 1.882.440
ERC STG

Exposing hidden targets of drug resistance in cancer by mapping the epitranscriptome at single-cell resolution

This project aims to develop a method for single-cell m6A mapping in breast cancer to uncover novel drug resistance targets and improve therapeutic strategies against chemoresistance.

€ 1.496.578